Evidence map›Paper›PMID 40416963›Full record

ArticleFrontiers in immunology2025

Efficacy of toripalimab in combination with anlotinib in recurrent undifferentiated pleomorphic sarcoma of the sinonasal region: a case report with biomarker analysis.

Fang Wu, Junqiao Feng, Hong Wang, Shan Wang, Xiaoguang Cui, Ying Liu, Linli Yan, Kaihong Ye, Rick F Thorne, Xu Dong Zhang and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fang WuDepartment of Oncology, the First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, China.
Junqiao FengNational-Local Joint Engineering Research Center of Biodiagnosis & Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Hong WangPrecision Medical Research Institute, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Shan WangPrecision Medical Research Institute, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xiaoguang CuiDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Ying LiuDepartment of Radiology, the First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, China.
Linli YanDepartment of Pathology, the First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, China.
Kaihong YeTranslational Research Institute of Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Rick F ThorneTranslational Research Institute of Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Xu Dong ZhangTranslational Research Institute of Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Ting LaNational-Local Joint Engineering Research Center of Biodiagnosis & Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Soft tissue sarcoma (STS) typically originates in the muscles and is associated with a poor prognosis. Undifferentiated pleomorphic sarcoma (UPS) is the most commonly diagnosed subtype of STS; however, UPS occurring in the sinonasal region is exceedingly rare and lacks effective treatment options. Objective: This case report presents a patient with sinonasal UPS who experienced disease progression after surgery and chemotherapy but showed a positive response to combination therapy with toripalimab and anlotinib. Additionally, it explores the underlying biomarkers associated with this case. Case: A 63-year-old woman with no significant past medical history was diagnosed with sinonasal UPS. The lesions recurred despite seven extensive surgical resections, and standard chemotherapy failed to control the disease, leading to progressive disease (PD). Results: The patient was treated with a combination of toripalimab and anlotinib, resulting in a significant partial response (PR) after just two cycles. Continued PR was observed after an additional six cycles, indicating the potential for a prolonged response with ongoing therapy. Genotyping and immunohistochemistry revealed that the sarcoma cells were rapidly dividing and enriched in vasculature prior to systemic treatment. Conclusion: These findings suggest that the combination of toripalimab and anlotinib may be an effective treatment option for advanced cases of UPS in the sinonasal region.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorIndolesParanasal Sinus NeoplasmsQuinolinesSarcomaAntibodies, Monoclonal, HumanizedFemaleHumansMiddle AgedNeoplasm Recurrence, LocalTreatment OutcomeanlotinibAntibodies, Monoclonal, HumanizedBiomarkers, TumorIndolesQuinolinestoripalimabanlotinibcase reportrecurrencetoripalimabundifferentiated pleomorphic sarcoma

Identifiers

PMID40416963
PMCPMC12098334

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.